

Special Issue

Novel Therapies for Pediatric Acute Myeloid Leukemia

Message from the Guest Editor

Approximately two-thirds of children and adolescents with acute myeloid leukemia (AML) are cured with modern risk-adapted therapy comprised of multi-agent chemotherapy and often hematopoietic stem cell transplantation. Current pediatric regimens are maximally intensive and are associated with both short- and long-term toxicity. Chemotherapy resistance nonetheless remains a major barrier to cure, highlighting a need for new therapies, potentially with alternative mechanisms of action. Recent advances in the molecular genetic characterization of pediatric AML and measurable residual disease (MRD) quantification and the correlation of these data with clinical outcomes have further refined risk stratification and recommended treatment protocols. Finally, increasing the availability of promising novel chemotherapies, small molecule inhibitors, and immunotherapies together with global collaboration has facilitated the development of innovative early-phase clinical trials specifically for children with high-risk or relapsed/refractory AML.

Guest Editor

Dr. Sarah K. Tasian

Children's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, Philadelphia, United States

Deadline for manuscript submissions

closed (28 February 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/48535

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)